Clinical Trial Update: A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating chidamide in combination with camrelizumab and either carboplatin or capecitabine for second/third line relapsed/metastatic tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Camrelizumab (camrelizumab)
• Capecitabine (capecitabine)
• Chidamide (chidamide)

Snippet

Sponsor: Fudan University | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN